EMA (European Medicines Agency) Guidelines

EMA Guidelines for Clinical Trials and Drug Approvals: A Complete Overview

Posted on digi By digi

Founded in 1995, the EMA harmonizes the work of national regulatory agencies within the European Economic Area (EEA). It offers centralized review procedures, scientific advice, and post-approval monitoring, fostering efficient access to medicines while protecting public health. Navigating EMA regulatory processes requires a deep understanding of clinical trial regulations, marketing authorization pathways, and post-marketing obligations.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

EMA Regulatory Requirements for Herbal Medicines: A Detailed Overview

Posted on digi By digi

While herbal products are derived from natural sources, the assumption that they are inherently safe is misleading. Active ingredients in plant-derived products can cause pharmacological effects, interact with other drugs, or lead to adverse events. The European Medicines Agency (EMA) ensures that herbal products meet the same high standards applied to conventional pharmaceuticals under EU directives and regulations.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

EMA Inspection Metrics and Common Findings: A Regulatory Perspective

Posted on digi By digi

EMA inspections are part of a harmonized regulatory framework designed to ensure the quality, safety, and efficacy of medicinal products authorized for use in the EU. These inspections are carried out either directly by the EMA or by national competent authorities (NCAs) of EU member states under EMA coordination.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

How to Report SUSARs to EMA via EudraVigilance: A Step-by-Step Guide

Posted on digi By digi

A SUSAR is a serious adverse reaction to a medicinal product that is both unexpected (not consistent with the product’s Investigator’s Brochure or Summary of Product Characteristics) and suspected to be related to the investigational medicinal product. Reporting SUSARs promptly helps protect clinical trial subjects and ensures regulatory compliance.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Centralised Marketing Authorisation Procedure under EMA: A Complete Regulatory Guide

Posted on digi By digi

The Centralised Marketing Authorisation Procedure allows sponsors to submit one application, undergo a single scientific evaluation by the EMA’s Committee for Medicinal Products for Human Use (CHMP), and receive a binding decision from the European Commission (EC) valid in all EU and EEA countries. This harmonised process ensures consistency in drug approval, especially for innovative and high-impact medicinal products.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

EMA Guidance on Good Clinical Practice (GCP): Ensuring Ethical and Compliant Trials in Europe

Posted on digi By digi

Good Clinical Practice is an international quality standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. It ensures the protection of trial subjects and the credibility of trial data. EMA has adopted ICH E6 (R2) GCP as the baseline requirement for all EU clinical trials.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Orphan Designation Criteria under EMA: A Regulatory Guide for Rare Disease Drug Development

Posted on digi By digi

Orphan designation is a status granted by EMA to medicinal products intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating rare conditions. It is designed to encourage investment in areas with unmet medical needs and small patient populations.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines